❌

Reading view

Disclaimers and Referral Patterns for Medical Advice Across Urgency Levels: Large Language Model Evaluation Study

Background: “I’m not a doctor, but...” is a typical response when asking considerate laypeople for health advice. However, seeking medical advice has also shifted to digital settings, where the expertise of the other party is less transparent than in face-to-face interactions. Recently, large language models (LLMs) have emerged as easily accessible tools, offering a novel way to formulate medical questions and receive seemingly qualified advice. Given the sensitive nature of health-related queries and the lack of professional supervision, incorrect advice can pose serious health risks. Therefore, including explicit disclaimers and precise referrals in LLM responses to medical queries is crucial. However, little is known about how LLMs adapt their safety implementations in response to different urgency levels. Objective: This study evaluates disclaimer and referral patterns in responses from LLMs to authentic medical queries of different urgency levels using a systematic evaluation framework. Methods: This prospective, multimodel evaluation study generated and analyzed 908 responses from 4 popular LLMs (GPT-4o, Claude Sonnet-4, Grok-3, and DeepSeek-V3) to 227 authentic patient queries from a public dataset. Two human raters classified all 227 patient queries using a 3-level urgency scale. LLM responses were evaluated using a 5-point ordinal classification system for disclaimer and referral advice, ranging from “no disclaimer” to “urgent advice to consult a medical professional.” GPT-4o served as the primary rater model for this task after conducting a subset validation against human expert annotations. Statistical analyses included Jonckheere-Terpstra tests to examine the relationship between case urgency and disclaimer ratings and Kruskal-Wallis tests for intermodel comparisons. Results: The 227 patient queries were distributed as 77 (34%) low-urgency, 110 (48%) intermediate-urgency, and 40 (18%) high-urgency cases. All 4 LLMs demonstrated statistically significant ordered trends (all
  •  

Insulin resistance prediction from wearables and routine blood biomarkers

Nature, Published online: 16 March 2026; doi:10.1038/s41586-026-10179-2

A machine-learning model that integrates data from wearable devices (such as smartwatches) with blood biomarkers and demographic data can predict whether someone has insulin resistance, enabling timely lifestyle interventions to prevent progression to type 2 diabetes.
  •  

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04306-9

In cohort 4 of the ILUSTRO trial, combination of anti-CLDN18.2 zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive, HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma led to encouraging clinical efficacy, supporting the testing of this combination in a phase 3 trial.
  •  
  •  

LINC-AC092535.5 regulates MICAL2 mRNA level to inhibit p53-mediated ferroptosis in nasopharyngeal carcinoma

Oncogene, Published online: 14 March 2026; doi:10.1038/s41388-026-03714-y

LINC-AC092535.5 regulates MICAL2 mRNA level to inhibit p53-mediated ferroptosis in nasopharyngeal carcinoma
  •  
❌